| Date | Title | Description |
| 18.03.2025 | BioArctic: Pioneering Hope in Neurodegenerative Disease Treatment | In the realm of medical innovation, few companies shine as brightly as BioArctic AB. This Swedish biopharma company is at the forefront of developing treatments for neurodegenerative diseases, a field often overshadowed by the complexity of... |
| 17.03.2025 | BioArctic receives Orphan Drug Designation for exidavnemab the US | BioArctic receives Orphan Drug Designation for exidavnemab the US
Mon, Mar 17, 2025 18:25 CET Report this content
Stockholm, March 17, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Pr... |
| 12.03.2025 | Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize | Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize
Wed, Mar 12, 2025 08:00 CET Report this content
Stockholm, Sweden, March 12, 2025 – Uppsala University announced today tha... |
| 06.03.2025 | The Lecanemab Dilemma: A Setback in Alzheimer’s Treatment in Australia | In a world where time is a precious commodity, the recent decision by Australia’s Therapeutic Goods Administration (TGA) to decline the registration of lecanemab for early Alzheimer’s disease (AD) feels like a cruel twist of fate. The drug,... |
| 06.03.2025 | Funding Cuts: A Looming Crisis in Global Health | In the realm of global health, funding is the lifeblood. Without it, progress stagnates, and lives hang in the balance. Recently, the World Health Organization (WHO) sounded the alarm. The United States, a key player in global health fundin... |
| 06.03.2025 | The Sound of Silence: WHO and ITU's New Standard for Gamers' Hearing Health | In a world where gaming has become a cultural phenomenon, the sound of victory often drowns out the whispers of caution. The World Health Organization (WHO) and the International Telecommunication Union (ITU) have stepped into this arena, l... |
| 03.03.2025 | Therapeutic Goods Administration decides not to register lecanemab in Australia | Therapeutic Goods Administration decides not to register lecanemab in Australia
Mon, Mar 03, 2025 09:00 CET Report this content
Stockholm, Sweden, March 3, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced toda... |
| 28.02.2025 | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU
Fri, Feb 28, 2025 14:00 CET Report this content
Stockholm, February 28, 2025 – BioArctic AB’s (publ) (... |
| 28.02.2025 | Number of shares and votes in BioArctic AB (publ) as of February 28, 2025 | Number of shares and votes in BioArctic AB (publ) as of February 28, 2025
Fri, Feb 28, 2025 18:30 CET Report this content
Stockholm, February 28,2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during F... |
| 20.02.2025 | BioArctic's Bold Moves in Alzheimer's Treatment: A New Era of Hope | In the world of biopharmaceuticals, the race against neurodegenerative diseases is relentless. BioArctic AB, a Swedish company, is at the forefront of this battle, armed with innovative technologies and strategic partnerships. Recent develo... |
| 20.02.2025 | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Thu, Feb 20, 2025 06:30 CET Report this content
Stockholm, Sweden, February 20, 2... |
| 18.02.2025 | Leqembi® sales reaches €200 million – first sales milestone achieved | Leqembi® sales reaches €200 million – first sales milestone achieved
Tue, Feb 18, 2025 08:00 CET Report this content
Stockholm, Sweden, February 18, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArcti... |
| 17.02.2025 | The Future of Pharmaceuticals: Innovations and Challenges in 2025 | The pharmaceutical landscape is shifting. New technologies and innovative treatments are emerging, promising to change the way we approach healthcare. In 2025, two companies stand at the forefront: BioArctic and TAHO Pharmaceuticals. Each i... |
| 13.02.2025 | FreeOx Biotech Celebrates Landmark 2024 with Record Growth: New Hires, Groundbreaking Trial Selections, and Major Funding Milestones | FreeOx Biotech
Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations
BARCELONA and PALO ALTO, Feb. 13, 2025 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical-stage ... |
| 13.02.2025 | Interim Report for the period October – December 2024 | Interim Report for the period October – December 2024
Thu, Feb 13, 2025 08:00 CET Report this content
Pioneering license agreement with BrainTransporter™ signed with BMS worth up to USD 1.35 billion plus royalties
Events during the fourth q... |
| 11.02.2025 | Gamified screening tool in Singapore detects early dementia in 15 minutes | Photo courtesy of Nanyang Technological University, Singapore
A new AI-based tool that gamifies the screening of mild cognitive impairment has been incorporated into a comprehensive health screening service in Singapore.
ReCOGnAIze is a neu... |
| 07.02.2025 | Sobi and Medidata: Two Titans Transforming Healthcare with Innovation and Insight | In the ever-evolving landscape of healthcare, two companies stand out: Sobi and Medidata. Each is a beacon of innovation, charting new territories in biopharmaceuticals and life sciences. Their recent reports reveal not just numbers, but a ... |
| 07.02.2025 | Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024 | Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024
Fri, Feb 07, 2025 04:35 CET Report this content
Stockholm, Sweden, February 7, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their qu... |
| 06.02.2025 | Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances | In the era of the generative economy, Medidata is transforming how industries are empowering patients with new cure and care experiences and lifelong engagement
SINGAPORE, Feb. 6, 2025 /PRNewswire/ -- Medidata, a Dassault Systèmes brand, re... |
| 05.02.2025 | Invitation to presentation of BioArctic’s fourth quarter report for October - December 2024 | Invitation to presentation of BioArctic’s fourth quarter report for October - December 2024
Wed, Feb 05, 2025 08:30 CET Report this content
Stockholm, Sweden, February 5, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish th... |
| 31.01.2025 | Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union | Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union
Fri, Jan 31, 2025 12:30 CET Report this content
Stockholm, January 31, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner... |
| 31.01.2025 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 27.01.2025 | FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US | FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US
Mon, Jan 27, 2025 00:30 CET Report this content
Stockholm, January 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BI... |
| 26.01.2025 | FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression an... |
| 15.01.2025 | Revolutionizing Alzheimer’s Treatment: The Rise of Leqembi and the Future of Pharma | In the world of pharmaceuticals, change is often slow. But every so often, a breakthrough emerges that promises to reshape the landscape. Leqembi, a drug developed to combat Alzheimer’s disease, is one such breakthrough. Recently, the U.S. ... |
| 14.01.2025 | FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option
TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. ... |
| 14.01.2025 | FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Tue, Jan 14, 2025 01:00 CET Report this content
Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B... |
| 14.01.2025 | From legacy systems to AI-power: How an Icelandic startup is transforming pharmaceutical supply chains | When supply chain startup PLAIO reached out to 300 mid-sized pharmaceutical companies, it discovered that an overwhelming 95 per cent of them rely on outdated spreadsheets for supply chain planning.
In response, the Icelandic startup, found... |
| 13.01.2025 | FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 10.01.2025 | The decade-long wait ends: A breakthrough in gout treatment | When it comes to metabolic diseases, conditions like diabetes and hyperlipidemia often dominate the conversation. Over recent years, pharmaceutical companies and investors have funneled substantial resources into these areas. Semaglutide, a... |
| 09.01.2025 | Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment | (Bloomberg) -- Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking the first treatment progress for them in decades.
Two late-stage studies published Wednesday in... |
| 19.12.2024 | BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program | BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program
Thu, Dec 19, 2024 07:30 CET Report this content
Stockholm, Sweden, December 19, 2024 – BioArctic AB (publ) (N... |
| 18.12.2024 | Eli Lilly's Alzheimer's treatment approved in China | Eli Lilly's Alzheimer's treatment approved in China
By ReutersDecember 18, 20242:24 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Eli Lilly logo is shown on one of the company's offices in San... |
| 05.12.2024 | First patient dosed in EXIST Phase 2a study in Parkinson’s disease | First patient dosed in EXIST Phase 2a study in Parkinson’s disease
Thu, Dec 05, 2024 08:00 CET Report this content
Stockholm, December 5, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been ... |
| 30.11.2024 | Leqembi's Launch: A New Dawn for Alzheimer's Treatment in South Korea | In a significant stride for Alzheimer's treatment, BioArctic AB's partner, Eisai, has launched Leqembi® (lecanemab) in South Korea. This approval, granted in May 2024, marks a pivotal moment for the nearly 900,000 dementia patients in the c... |
| 29.11.2024 | Number of shares and votes in BioArctic AB (publ) as of November 29, 2024 | Number of shares and votes in BioArctic AB (publ) as of November 29, 2024
Fri, Nov 29, 2024 18:30 CET Report this content
Stockholm, November 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during ... |
| 28.11.2024 | Leqembi[®] launched in South Korea | Leqembi[®] launched in South Korea
Thu, Nov 28, 2024 00:30 CET Report this content
Stockholm, Sweden, November 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (generic name: leca... |
| 24.11.2024 | Navigating the Sleep Science Frontier: A New Era for Hypersomnolence Treatment | Sleep is a complex puzzle. For many, it’s a sanctuary. For others, it’s a battleground. Central disorders of hypersomnolence, like narcolepsy and idiopathic hypersomnia, turn sleep into a foe. These conditions cause excessive daytime sleepi... |
| 18.11.2024 | State-of-the-science webinar will explore narcolepsy and hypersomnia | Sleep Research Society Foundation
Free webinar from the Sleep Research Society Foundation is Monday, Dec. 2.
DARIEN, Ill., Nov. 18, 2024 /PRNewswire-PRWeb/ -- The Sleep Research Society Foundation is hosting a state-of-the-science webinar, ... |
| 15.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the world of Alzheimer’s treatment, a new star is rising. Lecanemab, a monoclonal antibody developed by BioArctic and Eisai, is gaining traction. Recently, the European Medicines Agency’s Committee for Medicinal Products for Human Use (C... |
| 14.11.2024 | CHMP issues positive recommendation for approval of lecanemab in the EU | CHMP issues positive recommendation for approval of lecanemab in the EU
Thu, Nov 14, 2024 17:01 CET Report this content
Stockholm, November 14, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA’s Committee for M... |
| 14.11.2024 | Interim Report for the period July – September 2024 | Interim Report for the period July – September 2024
Thu, Nov 14, 2024 08:00 CET Report this content
Over 60 percent higher royalties than previous quarter
Events during the third quarter 2024 Leqembi® received approval and launched in Hong ... |
| 11.11.2024 | Medivir’s CEO: “There is an obvious need for fostrox” | Medivir’s CEO: “There is an obvious need for fostrox”
Mon, Nov 11, 2024 09:55 CET Report this content
Medivir has gone through an eventful period, marked by the presentation of clinical results at ESMO and a new collaboration agreement with... |
| 09.11.2024 | The Rising Tide of Biotech: Boston's Role in Global Health Transformation | Boston's biotech industry is a lighthouse in the stormy seas of global health challenges. It shines brightly, guiding innovation and collaboration. This city, with its prestigious universities and a vibrant network of biotech firms, has bec... |
| 08.11.2024 | Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion | Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion
Fri, Nov 08, 2024 05:00 CET Report this content
Stockholm, Sweden, November 8, 2024 – BioArctic AB's (publ) (Nasdaq ... |
| 06.11.2024 | BrainTransporter™ dramatically improves antibody delivery to the brain | BrainTransporter™ dramatically improves antibody delivery to the brain
Wed, Nov 06, 2024 15:00 CET Report this content
Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has presented the design of its prop... |
| 06.11.2024 | Invitation to presentation of BioArctic’s third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
Wed, Nov 06, 2024 08:30 CET Report this content
Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stock... |
| 04.11.2024 | BioStock: Medivir signs new clinical trial collaboration with Eisai | BioStock: Medivir signs new clinical trial collaboration with Eisai
Mon, Nov 04, 2024 16:41 CET Report this content
Medivir has entered into a clinical trial collaboration and supply agreement with Eisai to evaluate its liver-targeted treat... |
| 03.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the labyrinth of Alzheimer’s disease, a new light flickers. Lecanemab, a monoclonal antibody, has emerged as a promising treatment, showing potential to slow cognitive decline in early-stage patients. Recent data presented at the Clinica... |
| 01.11.2024 | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Fri, Nov 01, 2024 00:30 CET Report this content
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 31.10.2024 | The Rise of Leqembi: A New Dawn in Alzheimer’s Treatment | In the world of Alzheimer’s research, a beacon of hope shines brighter than ever. Leqembi, a drug developed through a partnership between BioArctic and Eisai, is making waves. The latest reports reveal that Leqembi generated JPY 10 billion ... |
| 31.10.2024 | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Thu, Oct 31, 2024 08:30 CET Report this content
Stockholm, Sweden October 31, 2024 – BioArctic AB’... |
| 30.10.2024 | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference | -New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab -
- Utilization of blood biomarkers to predict brain amyloid accumulati... |
| 30.10.2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Wed, Oct 30, 2024 11:45 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.10.2024 | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Wed, Oct 30, 2024 08:30 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Na... |
| 29.10.2024 | Massachusetts: The Beacon of Sustainable Biotech Innovation | Massachusetts is a powerhouse in biotechnology. It’s a state where innovation blooms like spring flowers. The rich soil of education, research, and collaboration nurtures groundbreaking advancements. This article explores how Massachusetts ... |
| 24.10.2024 | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
Thu, Oct 24, 2024 08:00 CET Report this content
Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented wit... |
| 17.10.2024 | BioArctic and Eisai: Navigating the Waters of Alzheimer’s Treatment | In the world of biopharma, few stories resonate as powerfully as the quest to combat Alzheimer’s disease. BioArctic AB, a Swedish company, stands at the forefront of this battle. Their flagship product, Leqembi® (lecanemab), has emerged as ... |
| 17.10.2024 | Eisai will request reconsideration of initial decision for lecanemab in Australia | Eisai will request reconsideration of initial decision for lecanemab in Australia
Thu, Oct 17, 2024 01:30 CET Report this content
Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced to... |
| 07.10.2024 | Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases, Upcoming Webinar Hosted by Xtalks | www.labcorp.com
In this free webinar, learn about the rapidly evolving landscape of Alzheimer's disease therapy development and treatment. Attendees will gain insights into the key considerations for various platforms and strategies to inco... |
| 03.10.2024 | Virtual dementia care platform Rippl scores $23M | Photo: Halfpoint Images/Getty Images
Rippl, a company focused on providing mental health solutions to seniors with dementia and other cognitive conditions, announced it closed a $23 million Series A funding round.
Tina Hoang-To, Kin Venture... |
| 30.09.2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024
Mon, Sep 30, 2024 18:30 CET Report this content
Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company durin... |
| 17.09.2024 | BioStock: Medivir – live from ESMO in Barcelona | BioStock: Medivir – live from ESMO in Barcelona
Tue, Sep 17, 2024 15:45 CET Report this content
At the ESMO conference in Barcelona, Medivir presented mature results from its ongoing Phase Ib/IIa trial of fostrox in combination with Lenvima... |
| 09.09.2024 | Пионер ксенотрансплантации eGenesis собрал $191 млн для генно-редактированных органов свиньи | Компания eGenesis уже попала в заголовки новостей благодаря трансплантации органов свиньи. В марте 2024 года eGenesis объявила о первой в мире успешной пересадке почки свиньи живому пациенту. Трансплантация была одобрена FDA в рамках расшир... |
| 04.09.2024 | eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages | eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici... |
| 04.09.2024 | eGenesis Raises $191M in Series B Funding | eGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding.
The round was led by Lux Capital, with participation from existing i... |
| 29.08.2024 | Interim Report for the period April – June 2024 | Interim Report for the period April – June 2024
Thu, Aug 29, 2024 08:00 CET Report this content
Lecanemab authorised in Great Britain and EU re-examination in progress
Events during the second quarter 2024 BioArctic and Eisai entered into a... |
| 27.08.2024 | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
Tue, Aug 27, 2024 08:00 CET Report this content
Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced toda... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 19.08.2024 | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
Mon, Aug 19, 2024 08:30 CET Report this content
Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 30.07.2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| 30.07.2024 | Long-term lecanemab data show increased patient benefit with maintained safety profile | Long-term lecanemab data show increased patient benefit with maintained safety profile
Tue, Jul 30, 2024 23:00 CET Report this content
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today pr... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alz... | - 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing... |
| 27.07.2024 | Lecanemab's EU Setback: A Race Against Time for Alzheimer's Treatment | In a world where time is a precious commodity, the recent decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent ripples of disappointment through the Alzheimer’s community. On ... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 27.07.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | The Alzheimer’s Association International Conference (AAIC) 2024 is set to unveil groundbreaking data on lecanemab, a drug that could reshape the landscape of Alzheimer’s disease (AD) treatment. As the conference approaches, excitement is p... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.07.2024 | Eisai will seek re-examination of CHMP opinion för lecanemab | Eisai will seek re-examination of CHMP opinion för lecanemab
Fri, Jul 26, 2024 13:15 CET Report this content
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will req... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.07.2024 | CHMP has adopted a negative opinion on lecanemab for the EU | CHMP has adopted a negative opinion on lecanemab for the EU
Fri, Jul 26, 2024 12:40 CET Report this content
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) h... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 23.07.2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024
Tue, Jul 23, 2024 08:00 CET Report this content
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will presen... |
| 22.07.2024 | EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2024 | Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues... |
| 12.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Israel | Leqembi approved for the treatment of Alzheimer’s disease in Israel
Fri, Jul 12, 2024 01:30 CET Report this content
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqem... |
| 11.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
Thu, Jul 11, 2024 01:30 CET Report this content
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that th... |
| 03.07.2024 | FDA Approves New Alzheimer's Drug, Bringing Hope of Slowing Disease for US Patients | By Inno Flores
Published Jul 3, 2024 4:14AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
The US Food and Drug Administration (FDA) gave a green light to a new Alzheimer's drug t... |
| 03.07.2024 | FDA approves new Alzheimer's treatment, donanemab from Eli Lilly | The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of t... |
| 02.07.2024 | Lilly's Alzheimer's drug gets FDA nod | figcaption>span]:font-sans" data-chromatic="ignore">
The Food and Drug Administration granted approval to Eli Lilly's Alzheimer's drug, which was found to slow progression of the disease by about a third, the company an... |
| 28.06.2024 | Number of shares and votes in BioArctic AB (publ) as of June 28, 2024 | Number of shares and votes in BioArctic AB (publ) as of June 28, 2024
Fri, Jun 28, 2024 18:30 CET Report this content
Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June iss... |
| 28.06.2024 | Leqembi[®] (lecanemab) launched in China | Leqembi[®] (lecanemab) launched in China
Fri, Jun 28, 2024 01:30 CET Report this content
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in Ch... |
| 27.06.2024 | “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China | TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 25.06.2024 | TPG: Significant Strategic Growth Investment In K2 Medical Research | Leading global alternative asset management firm TPG announced a significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform that specializes in central nervous system (CNS) trials for leading ... |
| 17.06.2024 | CARINGKIND RAISES $1.4 MILLION IN SUPPORT OF ALZHEIMER'S AND RELATED DEMENTIA CARE AT THE 28TH ANNUAL FORGET-ME-NOT GALA | NEW YORK, June 17, 2024 /PRNewswire/ -- CaringKind, the trusted partner in Alzheimer's and related dementia caregiving for over 45 years, hosted their 28th annual Forget-Me-Not Gala on Monday, June 3rd, 2024, at Cipriani 42nd Street. The no... |
| 14.06.2024 | Mission Based Media Launches "Health UNMUTED PLUS" for Ad-Free, Early Access on Apple Podcasts | New Subscription Service Empowers Listeners to Support Audio-First Health Information
NEW YORK, June 14, 2024 /PRNewswire/ -- Mission Based Media, a leading creator, producer and distributor of audio-first health education content, today an... |
